phenol has been researched along with Cerebral Palsy in 7 studies
Cerebral Palsy: A heterogeneous group of nonprogressive motor disorders caused by chronic brain injuries that originate in the prenatal period, perinatal period, or first few years of life. The four major subtypes are spastic, athetoid, ataxic, and mixed cerebral palsy, with spastic forms being the most common. The motor disorder may range from difficulties with fine motor control to severe spasticity (see MUSCLE SPASTICITY) in all limbs. Spastic diplegia (Little disease) is the most common subtype, and is characterized by spasticity that is more prominent in the legs than in the arms. Pathologically, this condition may be associated with LEUKOMALACIA, PERIVENTRICULAR. (From Dev Med Child Neurol 1998 Aug;40(8):520-7)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the treatment effectiveness of botulinum toxin type A (BTX-A) and phenol blocks in managing lower limb spasticity and gait dysfunction in children with cerebral palsy." | 7.72 | Clinical effects of botulinum toxin A and phenol block on gait in children with cerebral palsy. ( Chen, CL; Chen, CP; Chen, MJ; Chou, SW; Chung, CY; Wong, AM, 2004) |
| "To investigate the safety of single and repeated multilevel injections of botulinum toxin (BoNT) alone or a combination of phenol and BoNT performed under general anesthesia in children with chronic muscle spasticity." | 3.74 | Safety profile of multilevel chemical denervation procedures using phenol or botulinum toxin or both in a pediatric population. ( Ajizian, SJ; Kolaski, K; Koman, LA; Passmore, L; Pasutharnchat, N; Smith, BP, 2008) |
| "To compare the treatment effectiveness of botulinum toxin type A (BTX-A) and phenol blocks in managing lower limb spasticity and gait dysfunction in children with cerebral palsy." | 3.72 | Clinical effects of botulinum toxin A and phenol block on gait in children with cerebral palsy. ( Chen, CL; Chen, CP; Chen, MJ; Chou, SW; Chung, CY; Wong, AM, 2004) |
| "To describe the specific techniques and adverse reactions of using concurrent, multiple injections of both botulinum toxin and phenol to manage spasticity in children with cerebral palsy (CP) and other neurologic conditions." | 3.72 | Combining botulinum toxin and phenol to manage spasticity in children. ( Gooch, JL; Patton, CP, 2004) |
| "While in some children, spasticity may adversely impact the motor abilities, in others, it may help maintain posture and ability to ambulate." | 2.43 | Pharmacologic interventions for reducing spasticity in cerebral palsy. ( Patel, DR; Soyode, O, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ploypetch, T | 1 |
| Kwon, JY | 1 |
| Armstrong, HF | 1 |
| Kim, H | 1 |
| Kolaski, K | 1 |
| Ajizian, SJ | 1 |
| Passmore, L | 1 |
| Pasutharnchat, N | 1 |
| Koman, LA | 1 |
| Smith, BP | 1 |
| Wong, AM | 1 |
| Chen, CL | 1 |
| Chen, CP | 1 |
| Chou, SW | 1 |
| Chung, CY | 1 |
| Chen, MJ | 1 |
| Gooch, JL | 1 |
| Patton, CP | 1 |
| Patel, DR | 1 |
| Soyode, O | 1 |
| Tilton, AH | 1 |
| Goldstein, EM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Clinical Effect and Sonographic Findings of Kinesiotaping Combined With Therapeutic Exercise in Upper Extremity Spasticity and Function in Subacute Stroke Patients[NCT03024190] | 36 participants (Actual) | Interventional | 2017-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for phenol and Cerebral Palsy
| Article | Year |
|---|---|
Pharmacologic interventions for reducing spasticity in cerebral palsy.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Age Factors; Anti-Infective Agents, Local; Baclofen | 2005 |
Therapeutic interventions for tone abnormalities in cerebral palsy.
Topics: Administration, Oral; Anti-Dyskinesia Agents; Baclofen; Botulinum Toxins; Cerebral Palsy; Humans; Mu | 2006 |
Spasticity management: an overview.
Topics: Anti-Dyskinesia Agents; Baclofen; Botulinum Toxins; Cerebral Palsy; Child, Preschool; Exercise; GABA | 2001 |
4 other studies available for phenol and Cerebral Palsy
| Article | Year |
|---|---|
A Retrospective Review of Unintended Effects After Single-Event Multi-Level Chemoneurolysis With Botulinum Toxin-A and Phenol in Children With Cerebral Palsy.
Topics: Botulinum Toxins, Type A; Cerebral Palsy; Child; Child, Preschool; Female; Humans; Male; Muscle Spas | 2015 |
Safety profile of multilevel chemical denervation procedures using phenol or botulinum toxin or both in a pediatric population.
Topics: Age Factors; Anti-Dyskinesia Agents; Anti-Infective Agents, Local; Botulinum Toxins; Cerebral Palsy; | 2008 |
Clinical effects of botulinum toxin A and phenol block on gait in children with cerebral palsy.
Topics: Botulinum Toxins, Type A; Case-Control Studies; Cerebral Palsy; Child; Child, Preschool; Electromyog | 2004 |
Combining botulinum toxin and phenol to manage spasticity in children.
Topics: Adolescent; Botulinum Toxins, Type A; Cerebral Palsy; Child; Child, Preschool; Drug Therapy, Combina | 2004 |